Literature DB >> 15152926

Incorporation of functional imaging data in the evaluation of dose distributions using the generalized concept of equivalent uniform dose.

Moyed M Miften1, Shiva K Das, Min Su, Lawrence B Marks.   

Abstract

Advances in the fields of IMRT and functional imaging have greatly increased the prospect of escalating the dose to highly active or hypoxic tumour sub-volumes and steering the dose away from highly functional critical structure regions. However, current clinical treatment planning and evaluation tools assume homogeneous activity/function status in the tumour/critical structures. A method was developed to incorporate tumour/critical structure heterogeneous functionality in the generalized concept of equivalent uniform dose (EUD). The tumour and critical structures functional EUD (FEUD) values were calculated from the dose-function histogram (DFH), which relates dose to the fraction of total function value at that dose. The DFH incorporates flouro-deoxyglucose positron emission tomography (FDG-PET) functional data for tumour, which describes the distribution of metabolically active tumour clonogens, and single photon emission computed tomography (SPECT) perfusion data for critical structures. To demonstrate the utility of the method, the lung dose distributions of two non-small cell lung cancer patients, who received 3D conformal external beam radiotherapy treatment with curative intent, were evaluated. Differences between the calculated lungs EUD and FEUD values of up to 50% were observed in the 3D conformal plans. In addition, a non-small cell lung cancer patient was inversely planned with a target dose prescription of 76 Gy. Two IMRT plans (plan-A and plan-B) were generated for the patient based on the CT, FDG-PET and SPECT treatment planning images using dose-volume objective functions. The IMRT plans were generated with the goal of achieving more critical structures sparing in plan-B than plan-A. Results show the target volume EUD in plan-B is lower than plan-A by 5% with a value of 73.31 Gy, and the FEUD in plan-B is lower than plan-A by 2.6% with a value of 75.77 Gy. The FEUD plan-B values for heart and lungs were lower than plan-A by 22% and 18%, respectively. While EUD values show plan-A is marginally better than plan-B in terms of target volumetric coverage, the FEUD plan-B values show adequate target function coverage with significant critical structure function sparing. In conclusion, incorporating functional data in the calculation of EUD is important in evaluating the biological merit of treatment plans.

Entities:  

Mesh:

Year:  2004        PMID: 15152926     DOI: 10.1088/0031-9155/49/9/009

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  13 in total

Review 1.  Imaging radiation-induced normal tissue injury.

Authors:  Mike E Robbins; Judy K Brunso-Bechtold; Ann M Peiffer; Christina I Tsien; Janet E Bailey; Lawrence B Marks
Journal:  Radiat Res       Date:  2012-02-21       Impact factor: 2.841

2.  Evaluating Which Dose-Function Metrics Are Most Critical for Functional-Guided Radiation Therapy.

Authors:  Austin M Faught; Tokihiro Yamamoto; Richard Castillo; Edward Castillo; Jingjing Zhang; Moyed Miften; Yevgeniy Vinogradskiy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-04-08       Impact factor: 7.038

3.  Role of perfusion SPECT in prediction and measurement of pulmonary complications after radiotherapy for lung cancer.

Authors:  Katherina P Farr; Stine Kramer; Azza A Khalil; Anni Morsing; Cai Grau
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-11       Impact factor: 9.236

4.  Framework for radiation pneumonitis risk stratification based on anatomic and perfused lung dosimetry.

Authors:  Gurleen Dhami; Jing Zeng; Hubert J Vesselle; Paul E Kinahan; Robert S Miyaoka; Shilpen A Patel; Ramesh Rengan; Stephen R Bowen
Journal:  Strahlenther Onkol       Date:  2017-03-02       Impact factor: 3.621

5.  Use of 4-dimensional computed tomography-based ventilation imaging to correlate lung dose and function with clinical outcomes.

Authors:  Yevgeniy Vinogradskiy; Richard Castillo; Edward Castillo; Susan L Tucker; Zhongxing Liao; Thomas Guerrero; Mary K Martel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-03-06       Impact factor: 7.038

6.  Dynamic MRI of grid-tagged hyperpolarized helium-3 for the assessment of lung motion during breathing.

Authors:  Jing Cai; Ke Sheng; Stanley H Benedict; Paul W Read; James M Larner; John P Mugler; Eduard E de Lange; Gordon D Cates; G Wilson Miller
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-06-18       Impact factor: 7.038

7.  Optimizing global liver function in radiation therapy treatment planning.

Authors:  Victor W Wu; Marina A Epelman; Hesheng Wang; H Edwin Romeijn; Mary Feng; Yue Cao; Randall K Ten Haken; Martha M Matuszak
Journal:  Phys Med Biol       Date:  2016-08-12       Impact factor: 3.609

8.  Four-dimensional computed tomography-based biomechanical measurements of pulmonary function and their correlation with clinical outcome for lung stereotactic body radiation therapy patients.

Authors:  Hoda Sharifi; Gary C McDonald; Joon Kyu Lee; Munther I Ajlouni; Indrin J Chetty; Hualiang Zhong
Journal:  Quant Imaging Med Surg       Date:  2019-07

9.  Feasibility of image registration and intensity-modulated radiotherapy planning with hyperpolarized helium-3 magnetic resonance imaging for non-small-cell lung cancer.

Authors:  Rob H Ireland; Chris M Bragg; Mark McJury; Neil Woodhouse; Stan Fichele; Edwin J R van Beek; Jim M Wild; Matthew Q Hatton
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-01       Impact factor: 7.038

10.  Hyperpolarized 129Xe Magnetic Resonance Imaging for Functional Avoidance Treatment Planning in Thoracic Radiation Therapy: A Comparison of Ventilation- and Gas Exchange-Guided Treatment Plans.

Authors:  Leith J Rankine; Ziyi Wang; Chris R Kelsey; Elianna Bier; Bastiaan Driehuys; Lawrence B Marks; Shiva K Das
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-07-13       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.